Last10K.com

Actavis, Inc. (ACT) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2012

Actavis, Inc.

CIK: 884629

EXHIBIT 99.1

 

LOGO   

NEWS RELEASE

 

  CONTACTS:    Investors:
     Lisa DeFrancesco
     (862) 261-7152
     Media:
     Charlie Mayr
     (862) 261-8030

Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion

- 26% Increase in Full Year 2012 Non-GAAP EPS to $6.00; GAAP EPS $0.76 -

- Fourth Quarter 2012 Net Revenue of $1.75 Billion -

- Fourth Quarter 2012 Non-GAAP EPS of $1.59; GAAP EPS $0.21 -

- Company Reaffirms 2013 Forecast -

PARSIPPANY, NJ – February 19, 2013 – Actavis, Inc. (NYSE: ACT) today reported net revenue increased 13 percent to $1.75 billion for the fourth quarter 2012, compared to $1.54 billion in the fourth quarter 2011. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2012 was $1.59, compared to $1.77 per diluted share in the fourth quarter 2011, a decline of 10%. GAAP earnings per diluted share for the fourth quarter 2012 were $0.21, compared to $0.75 in the prior year period. Fourth quarter 2011 earnings includes the launch of generic Lipitor® which contributed $0.64 of non-GAAP earnings per diluted share to the prior-year period compared to $0.03 in the fourth quarter of 2012.

For the fourth quarter 2012, adjusted EBITDA was $393.0 million, compared to $393.4 million for the fourth quarter 2011. Cash and marketable securities were $328.0 million as of December 31, 2012.

For the full year 2012, net revenue increased 29 percent to $5.9 billion, compared to net revenue of $4.6 billion for full year 2011. On a non-GAAP basis, 2012 earnings per diluted share increased 26% to $6.00 per diluted share compared $4.77 per diluted share in 2011. GAAP earnings per diluted share were $0.76 for the full year 2012, compared to $2.06 in 2011.

 

1


The following information was filed by Actavis, Inc. on Tuesday, February 19, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Actavis, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actavis, Inc..

Continue

Assess how Actavis, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actavis, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Acquisitions And Divestitures
Acquisitions And Divestitures (tables)
Acquisitions And Divestitures - Additional Information (detail)
Acquisitions And Divestitures - Allocation Of Consideration Transferred (detail)
Acquisitions And Divestitures - Unaudited Pro Forma Results Of Operations (detail)
Balance Sheet Components
Balance Sheet Components (tables)
Balance Sheet Components - Selected Balance Sheet Components (detail)
Business Restructuring Charges
Business Restructuring Charges (tables)
Business Restructuring Charges - Additional Information (detail)
Business Restructuring Charges - Schedule Of Activity Related To Business Restructuring And Facility Rationalization (detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities - Additional Information (detail)
Description Of Business
Description Of Business - Additional Information (detail)
Fair Value Measurement
Fair Value Measurement (tables)
Fair Value Measurement - Additional Information (detail)
Fair Value Measurement - Schedule Of Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (detail)
Fair Value Measurement - Summary Of Changes In Fair Value Of All Financial Assets And Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (detail)
Goodwill, Product Rights And Other Intangible Assets
Goodwill, Product Rights And Other Intangible Assets (tables)
Goodwill, Product Rights And Other Intangible Assets - Additional Information (detail)
Goodwill, Product Rights And Other Intangible Assets - Goodwill (detail)
Goodwill, Product Rights And Other Intangible Assets - Intangible Assets With Definite And Indefinite Lives (detail)
Goodwill, Product Rights And Other Intangible Assets - Schedule Of Annual Amortization Expense On Product Rights And Related Intangibles (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Schedule Of Components Company's Net Deferred Tax Assets (liabilities) (detail)
Income Taxes - Schedule Of Income Before Provision For Income Taxes (detail)
Income Taxes - Schedule Of Provision For Income Taxes (detail)
Income Taxes - Schedule Of Reconciliation Of Unrecognized Tax Benefits (detail)
Income Taxes - Schedule Of Reconciliations Between Statutory Federal Income Tax Rate And Company's Effective Income Tax Rate (detail)
Investments In Marketable Securities And Other Investments
Investments In Marketable Securities And Other Investments (tables)
Investments In Marketable Securities And Other Investments - Additional Information (detail)
Investments In Marketable Securities And Other Investments - Marketable Securities And Other Investments (detail)
Investments In Marketable Securities And Other Investments - Summary Of Fair Value And Unrealized Gains (losses) Related To Available-for-sale Securities (detail)
Long-term Debt
Long-term Debt (tables)
Long-term Debt - Additional Information (detail)
Long-term Debt - Long-term Debt (detail)
Long-term Debt - Long-term Debt (parenthetical) (detail)
Long-term Debt - Schedule Of Annual Debt Maturities (detail)
Long-term Debt - Summary Of Assets Recorded Under Capital Leases (detail)
Long-term Debt - Summary Of Future Minimum Lease Payments Under Capital And Operating Leases (detail)
Other Income (expense)
Other Income (expense) (tables)
Other Income (expense) - Additional Information (detail)
Other Income (expense) - Components Of Other Income (detail)
Other Long-term Liabilities
Other Long-term Liabilities (tables)
Other Long-term Liabilities - Other Long-term Liabilities (detail)
Pension And Other Postretirement Benefit Plans
Pension And Other Postretirement Benefit Plans (tables)
Pension And Other Postretirement Benefit Plans - Additional Information (detail)
Pension And Other Postretirement Benefit Plans - Fair Values Of Pension Plan Assets By Asset Category (detail)
Pension And Other Postretirement Benefit Plans - Summarized Information About Changes In Plan Assets And Benefit Obligation, Funded Status And Amounts Recorded (detail)
Pension And Other Postretirement Benefit Plans - Summary Of Expected Benefit Payments (detail)
Pension And Other Postretirement Benefit Plans - Summary Of Weighted Average Assumptions Used In Determining Pension Plan Information (detail)
Schedule Ii - Valuation And Qualifying Accounts
Schedule Ii - Valuation And Qualifying Accounts (detail)
Segments
Segments (tables)
Segments - Additional Information (detail)
Segments - Schedule Of Net Product Sales By Geographic Areas (detail)
Segments - Schedule Of Net Product Sales By Therapeutic Categories (detail)
Segments - Schedule Of Net Revenues, Operating Expenses Contribution Information By Reportable Segment (detail)
Share-based Compensation
Share-based Compensation - Additional Information (detail)
Stockholders' Equity
Stockholders' Equity (tables)
Stockholders' Equity - Additional Information (detail)
Stockholders' Equity - Summary Of Changes In Restricted Stock Grants (detail)
Stockholders' Equity - Summary Of Company's Stock Option Plans (detail)
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Earnings Per Share (detail)
Summary Of Significant Accounting Policies - Property And Equipment (detail)
Summary Of Significant Accounting Policies - Provisions For Sales Returns And Allowances (detail)
CIK: 884629
Form Type: 10-K Annual Report
Accession Number: 0001193125-13-082059
Submitted to the SEC: Thu Feb 28 2013 8:16:36 AM EST
Accepted by the SEC: Thu Feb 28 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/884629/0001193125-13-082059.htm